NKTR Loses $36M, Trial Failures Spark Lawsuits

Nektar Therapeutics (NKTR) reported Q4 2025 earnings that fell short of expectations, marked by a significant net loss and declining revenue. The company’s results highlighted operational challenges despite a strong cash position and pipeline advancements.

Revenue

Nektar’s total revenue plummeted 25.3% year-over-year to $21.81 million in Q4 2025, driven entirely by non-cash royalty revenue tied to future royalties. This represented a stark decline from the $29.18 million reported in the prior-year period, underscoring a lack of diversification in revenue streams.

Earnings/Net Income

The company swung to a $1.78 per-share loss in Q4 2025, a 442.3% negative change from the $0.52 profit in Q4 2024. Net losses expanded to $36.08 million, a 596.9% deterioration compared to the $7.26 million net income a year earlier, reflecting heightened operational costs and unmet business objectives. The earnings performance signals a deteriorating financial outlook.

Price Action

NKTR shares fell 2.94% in a single trading day and 2.88% for the week, though they gained 89.80% month-to-date, indicating mixed investor sentiment.

Post-Earnings Price Action Review

The strategy of buying NKTR shares 30 days after earnings releases and holding for 30 days yielded no returns over three years, with a CAGR of 0.00% and a -62.97% excess return relative to a 62.97% benchmark. The approach, characterized by a 0.00% maximum drawdown and Sharpe ratio, appeared risk-free yet unprofitable.

CEO Commentary

CEO Howard Robin emphasized progress in Nektar’s immunology pipeline, particularly REZPEG’s phase 2b results in atopic dermatitis and alopecia areata. With $245.8 million in cash as of 2025’s end and an additional $476 million raised post-year-end, the company aims to initiate phase 3 trials in 2026, targeting a 2029 BLA submission. Robin framed REZPEG as a transformative therapy with a novel mechanism of action.

Guidance

Nektar provided 2026 guidance: $40–45 million in non-cash royalty revenue, $200–250 million in R&D expenses (including $5–10 million non-cash), $60–65 million in G&A expenses, $30–35 million in non-cash interest, and $400–460 million in ending cash. Phase 3 trials will drive R&D spending, with updated guidance pending mid-2028 data.

Additional News

Two securities fraud lawsuits were filed against Nektar following its December 2025 announcement that the REZOLVE-AA trial for alopecia areata failed to meet statistical significance. Glancy Prongay Wolke & Rotter LLP and Pomerantz Law Firm are representing investors who allege misleading statements. Shareholders are urged to contact these firms to pursue potential claims. Both lawsuits cite a 7.8% stock price drop on December 16, 2025, following the trial results disclosure.